54802-32-3

Basic information

• Product Name: 1-(3,4-dimethoxyphenyl)cyclohexanecarbonitrile
• Synonyms: 1-(3,4-dimethoxyphenyl)cyclohexanecarbonitrile
• CAS NO: 54802-32-3
• Molecular Weight: 245.321
• Mol File: 54802-32-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-(3,4-dimethoxyphenyl)cyclohexanecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-dimethoxyphenyl)cyclohexanecarbonitrile(54802-32-3)
• EPA Substance Registry System: 1-(3,4-dimethoxyphenyl)cyclohexanecarbonitrile(54802-32-3)

Safety Data

• Hazardous Substances Data: 54802-32-3(Hazardous Substances Data)

Upstream product

• 626-92-6 1,4-dichloropentane 
• 111-24-0 1,5-dibromo-pentane 
• 93-17-4 3,4-dimethoxyphenylacetonitrile 

Downstream Products

• 121139-49-9 N-[4-(3,4-Dimethoxyphenyl) butyl]-N-(1-methylethyl)-4-cyano-4-(3,4-dimethoxyphenyl)-1-aminocyclohexane Hydrochloride 
• 54802-31-2 1-(3,4-Dimethoxy-phenyl)-cyclohexanecarboxylic acid 
• 55092-70-1 C-[1-(3,4-dimethoxy-phenyl)-cyclohexyl]-methylamine 

Relevant articles and documents

Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design

Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disease whose pathogenesis cannot be defined by one single element but consists of various factors; thus, there is a call for alternative approaches to tackle the multifaceted aspects of AD. Among the potential alternative targets, we aim to focus on glutaminyl cyclase (QC), which reduces the toxic pyroform of β-amyloid in the brains of AD patients. On the basis of a putative active conformation of the prototype inhibitor 1, a series of N-substituted thiourea, urea, and α-substituted amide derivatives were developed. The structure-activity relationship analyses indicated that conformationally restrained inhibitors demonstrated much improved QC inhibition in vitro compared to nonrestricted analogues, and several selected compounds demonstrated desirable therapeutic activity in an AD mouse model. The conformational analysis of a representative inhibitor indicated that the inhibitor appeared to maintain the Z-E conformation at the active site, as it is critical for its potent activity.

Discovery and development of potent and selective inhibitors of histone methyltransferase G9a

G9a is a histone lysine methyltransferase responsible for the methylation of histone H3 lysine 9. The discovery of A-366 arose from a unique diversity screening hit, which was optimized by incorporation of a propyl-pyrrolidine subunit to occupy the enzyme

Novel arylcycloalkanepolyalkylamines

Novel arylcycloalkanepolyalkylamines useful as anti-psychotic, anti-ischemia, anti-stroke, anti-dementia and anti-convulsant agents. These arylcycloalkanepolyalkylamines are selective high-affinity ligands to the sigma binding-sites containing three basic units: arylcycloalkyl group, an amine group and an intermediate chain. Their preparation and use for treatment of psychoses, ischemia, stroke, dementia and convulsions are also disclosed.